Status:
COMPLETED
Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Transplantation
Eligibility:
All Genders
Brief Summary
The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.
Eligibility Criteria
Inclusion
- Transplantation patients treated with sirolimus (Rapamune).
Exclusion
- Patients must be able to give informed consent.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00195195
Start Date
January 1 2005
End Date
June 1 2008
Last Update
January 31 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Gothenburg, Sweden, SE-413 45
2
Stockholm, Sweden, SE-141 86
3
Uppsala, Sweden, SE-751 85